Department of Biochemistry and Genetics, School of Medicine, Zhejiang University, Hangzhou 310058, PR China.
Department of Pharmaceutical Analysis, College of Pharmaceutical Science, Zhejiang University, Hangzhou 310058, PR China.
Immunol Lett. 2017 Oct;190:34-41. doi: 10.1016/j.imlet.2017.06.004. Epub 2017 Jul 3.
Programmed cell death 1 ligand 1 (PD-L1) is a trans-membrane protein highly expressed on the membrane of cancer cell, which binds inhibitory receptor of PD-1 on the T cells and attenuates anti-tumor immune response.The strategy of blocking PD1 and PD-L1 interaction has been widely used for anti-cancer drug development. The DNA encoding extracellular domain of PD-L1 was cloned and expressed with the pET30(+) and Escherichia coli BL21(DE3) system. Cloning of PD-L1 extracellular domain was confirmed by PCR and enzymatic digestion. Sequence analysis of cloned targeted genes showed 100% homology of original sequence. The recombinant protein was expressed using 1mM/mL IPTG and purified by affinity chromatography on a column of Ni-NTA and confirmed by SDS-PAGE and western blot analysis. Results showed that our constructed pET30(+)/PDL1-ECD system efficiently produces desired recombinant protein with molecular weight of 38.1kDa. The prokaryotic expression system provides an easy method to express PD-L1 extracellular domain that further facilitate the role of PD-1/PD-L1 binding inhibition and helps in valuable drug and antibodies production.
程序性细胞死亡受体 1 配体 1(PD-L1)是一种高度表达在癌细胞膜上的跨膜蛋白,它与 T 细胞上的 PD-1 抑制性受体结合,从而减弱抗肿瘤免疫反应。阻断 PD1 和 PD-L1 相互作用的策略已广泛应用于抗癌药物的开发。使用 pET30(+)和大肠杆菌 BL21(DE3)系统克隆并表达了 PD-L1 胞外域的 DNA。通过 PCR 和酶切验证了 PD-L1 胞外域的克隆。对克隆的目的基因进行序列分析,显示原始序列的同源性为 100%。使用 1mM/mL IPTG 表达重组蛋白,并通过 Ni-NTA 柱亲和层析进行纯化,通过 SDS-PAGE 和 Western blot 分析进行验证。结果表明,我们构建的 pET30(+)/PDL1-ECD 系统能够有效地产生预期的重组蛋白,分子量为 38.1kDa。原核表达系统为表达 PD-L1 胞外域提供了一种简便的方法,进一步促进了 PD-1/PD-L1 结合抑制的作用,并有助于有价值的药物和抗体的生产。